With Luminex Corporation's ARIES MRSA Assay for Detection of MRSA getting FDA approval in the United States, the global hospital acquired disease testing market continues to grow.

 

Testing for hospital-acquired diseases can be done in a number of different ways. If the disease is new, hospital-acquired infections may be contracted from an infected person on the job. In such cases, hospital-acquired infections are commonly referred to as occupational-related diseases. As with other types of diseases, these infections can be caught through simple hand-to-mouth contact. The various methods of testing for this disease include clinical diagnostics and blood tests. If the clinical symptoms do not occur or present themselves slowly, laboratory testing is advisable. However, because symptoms can be similar to those of other diseases that affect the immune system, it is important to obtain a correct diagnosis.

Increasing incidence of hospital-acquired infections is expected to drive growth of the global hospital acquired disease testing market. According to the World Health Organization (WHO), of every 100 hospitalized patients 10 from emerging and 7 from developed countries will acquire at least one healthcare-related infection. According to the European Centre for Disease Prevention and Control, around 7.1% of Europeans get affected by hospital-acquired infections. Adequate sterilization and robust testing equipment can minimize the possibility of such infections and reduce healthcare expenditure. Hence, such factors are expected to drive growth of the global hospital disease testing market. Furthermore, increasing launching of novel and efficient testing tools is expected to propel the global hospital acquired disease testing market growth in the near future. For instance, in December 2019, Roche Ltd. received the U.S. Food and Drug Administration (FDA) approval for its Cobas ivoDx MRSA, a diagnostic test designed to detect the Methicillin-resistant Staphylococcus aureus (MRSA) bacteria.

Decreasing the prevalence of nosocomial infections due to the presence of advanced testing kits is expected to hamper the global hospital-acquired disease testing market growth in the near future. Among regions, North America is expected to witness significant growth in the global hospital-acquired disease testing market. This is owing to the presence of robust healthcare infrastructure and key market players such as Nordion Inc. and Luminex Corporation in the region. Furthermore, Europe is expected to register a lucrative growth rate, owing to increasing investment in healthcare infrastructure in the region.

Key companies involved in the global hospital acquired disease testing market are Luminex Corporation, Biomérieux, Diatherix Laboratories, F.Hoffmann-La Roche Ltd., Life Technologies, Qiagen GmbH, Cantel Medical Corporation, Nordion Inc., Meridian Biosciences Inc., and Cepheid.

For instance, in October 2019, Luminex Corporation received the U.S. FDA 510(k) clearance ARIES MRSA Assay for the direct detection of methicillin-resistant Staphylococcus aureus (MRSA) DNA.